BIO Europe 2025 in Vienna

• News

Medelis, a specialty oncology CRO focused on early-phase clinical trials, will attend BIO Europe 2025 this November in Vienna. CEO Dan Weng and VP Clinical Operations Brad Phillips will meet with emerging and mid-size biopharma sponsors developing novel cancer therapies to explore partnership opportunities.

Bridging Global Innovation to U.S. Oncology Execution

For more than two decades, Medelis has supported oncology programs from first-in-human through Phase II, delivering the focus and flexibility that global biopharma companies need when expanding to U.S. clinical sites.

Our model is intentionally different from large CROs:

• Oncology specialization – Every project is guided by oncology-experienced teams.
• Direct access to leadership – Sponsors work hands-on with Medelis executives from trial design through execution.
• Faster site activation – A proven network of U.S. oncology investigators enables rapid study startup.
• Right-sized partnership – Lean operations that scale without the overhead or delays of global CRO bureaucracy.

Meet Medelis at BIO Europe 2025

If you’re attending BIO Europe 2025 and planning or running oncology trials in the United States, we’d welcome the chance to connect. Bring your trial challenges — we’ll bring solutions.

📅 Schedule a private meeting: Request a meeting on PartneringONE
📍 Event: BIO Europe 2025 | November 3-5 | Vienna, Austria

Or contact us directly to arrange a Trial Acceleration Strategy Session with our leadership team.